

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

## Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
	appear
Company	General
Merck Sharp & Dohme	All Wales Therapeutics and Toxicology
(pembrolizumab)	Centre
,	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Asthma and Lung UK	Wales
Black Health Agency for Equality	British National Formulary
Cancer Black Care	Care Quality Commission
Cancer Equality	Department of Health, Social Services
Helen Rollason Cancer Charity	and Public Safety for Northern Ireland
Independent Cancer Patients Voice	Healthcare Improvement Scotland
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary Care
Oncogene-Driven Lung Cancer	National Pharmacy Association
Patient Alliance UK	NHS Confederation
Roy Castle Lung Cancer Foundation	Scottish Medicines Consortium
Ruth Strauss Foundation	Welsh Government
South Asian Health Foundation	Welsh Health Specialised Services
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	Commonstantonion
UK Lung Cancer Coalition	Comparator companies
1144	AstraZeneca (durvalumab, osimertinib)
Healthcare professional groups	Aspire Pharma (pemetrexed)     Brigger Myore Squibb (pixelymeb)
Association of Anaesthetists     Association of Conser Physicians	<ul> <li>Bristol Myers Squibb (nivolumab, paclitaxel)</li> </ul>
Association of Cancer Physicians     Association of Pagnitude Aluma	
Association of Respiratory Nurse     Specialists	<ul><li>Dr Reddy's Laboratories (pemetrexed)</li><li>Eli Lilly (pemetrexed)</li></ul>
Specialists  Association of Surgoons of Great	
<ul> <li>Association of Surgeons of Great Britain and Ireland</li> </ul>	<ul><li>Genus Pharmaceuticais (pemetrexed)</li><li>Medac (oxaliplatin)</li></ul>
British Geriatrics Society	Pfizer (cisplatin, carboplatin, docetaxel)
British Institute of Radiology	oxaliplatin, paclitaxel, pemetrexed)
British Oncology Pharmacy	Ranbaxy (oxaliplatin)
Association	Roche (atezolizumab)
British Psychosocial Oncology Society	Sandoz (cisplatin, pemetrexed)
British Society of Interventional	Seacross Pharmaceuticals (paclitaxel,

Final Stakeholder list for the evaluation of pembrolizumab (with chemotherapy) for neoadjuvant and adjuvant treatment (as monotherapy) of resectable non-small-cell lung cancer [ID5094] Issue date: January 2024



Consultees	Commentators (no right to submit or appeal)
<ul> <li>Radiology</li> <li>British Thoracic Oncology Group</li> <li>British Thoracic Society</li> <li>British Transplantation Society</li> <li>Cancer Research UK</li> <li>Lung Cancer and Mesothelioma Clinical Expert Group</li> <li>Lung Cancer Nursing UK</li> <li>National Heart and Lung Institute</li> <li>NHS Blood and Transplant</li> <li>Primary Care Respiratory Society</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed)  Relevant research groups Cochrane Lung Cancer Group Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research  Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final Stakeholder list for the evaluation of pembrolizumab (with chemotherapy) for neoadjuvant and adjuvant treatment (as monotherapy) of resectable non-small-cell lung cancer [ID5094] Issue date: January 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.